The endothelin system and its role in acute myocardial infarction

Expert Opinion on Therapeutic Targets

Volumn 8, Issue 3, 2004, Pages 191-201

  Doggrell, Sheila A ^a  

^a Doggrell Biomedical Communications   (New Zealand)

Author keywords

Acute myocardial infarction (AMI); Animal models of AMI; Endothelin (ET) 1; Endothelin receptor blockade; Endothelin converting enzyme (ECE) inhibition

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENRASENTAN; PD 161721; PHOSPHORAMIDON; PLACEBO; SM 19712; TAK 044; TEZOSENTAN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ARTERY OCCLUSION; CLINICAL TRIAL; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY DILATATION; CORONARY ARTERY RECANALIZATION; DISEASE MODEL; DOG; DRUG STRUCTURE; HEART ARRHYTHMIA; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROARRHYTHMIA; HEART VENTRICLE FAILURE; HUMAN; INOTROPISM; ISOLATED HEART; MOUSE; NONHUMAN; RABBIT; RAT; RECEPTOR BLOCKING; REVIEW; SWINE; TREATMENT OUTCOME;

ANIMALS; ENDOTHELIN-1; HUMANS; MYOCARDIAL INFARCTION; RECEPTOR, ENDOTHELIN A;

EID: 3042789987     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.8.3.191     Document Type: Review

References (78)

1. BOERSMA E, MERCADO N, POLDERMANS D et al.: Acute myocardial infarction. Lancet (2003) 361:847-858.
2. PIESKE B, BEYERMANN B, BREU V et al.: Functional effects of endothelin and regulation of endothelin receptors in isolated nonfailing and failing myocardium. Circulation (1999) 99:1802-1809.
3. B receptors in human myocardial trabeculae. Clin. Sci. (2000) 99:161-168.
4. PONICKE K, VOGELSANG M, HEINROTH M et al.: Endothetin receptors in the failing and nonfailing human heart. Circulation (1998) 97:744-751.
5. DHEIN S, GIESSLER C, WANGEMANN T et al.: Differential pattern of endothelin-1-induced inotropic effects on right atria and left ventricles of the failing heart. J. Cardiovasc. Pharmacol. (2000) 36:564-569.
6. KUSUMOTO K, AWANE Y, FUJIWARA S, WATANABE T. Role of endogenous endothelin in extension of rabbit myocardial infarction. J. Cardiovasc. Pharmacol. (1993) 22(Suppl. 8):339-342.
7. GROVER GJ, SLEPH PG, FOX M, TRIPPODO NC: Role of endothelin-1 and big endothelin-1 in modulating coronary vascular tone, contractile function and severity of ischemia in rat hearts. J. Pharmacol. Exp. Ther. (1992) 263:1074-1082.
8. BRUNNER F: Tissue endothelin-1 levels in perfused rat heart following stimulation with agonists and in ischaemia and reperfusion. J. Mol. Cell. Cardiol. (1995) 27:1953-1963.
9. YANG XP, MADEDDU P, MICHELETTI R et al.: Effects of intravenous endothelin on hemodynamics and cardiac contractility in conscious Milan normotensive rats. J. Cardiovasc. Pharmacol. (1991) 17:662-669.
10. DOMENCH R, MACHO P, GONZALEZ R, HUIDOBRO-TORO JP: Effect of endothelin on total and regional coronary resistance and on myocardial contractility. Eur. J. Pharmacol. (1991) 192:409-419.
11. SZOKODI I, HORKAY F, MERKELY B et al.: Intrapericardial infusion of endothelin-1 induced ventricular arrhythmias in dogs. Cardiovasc. Res. (1998) 38:356-364.
12. DOUGLAS SA, NICHOL AJ, FEUERSTEIN GZ et al.: SB 209670 inhibits the arrhythmogenic actions of endothelin in the anesthetized dog. J. Cardiovasc. Pharmacol. (1998) 31(Suppl. 1):99-102.
13. CLARKE JG, BENJAMIN N, LARKIN SW et al.: Endothelin is a potent long-lasting vasoconstrictor in men. Am. J. Physiol. (1989) 257:H2033-H2035.
14. CARDILLO C, KILCOYNE CM, WACLAWIW M, CANNON RO III, PANZA JA. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension (1999) 33:753-758.
15. CHESTER AH, DASHWOOD MR. CLARKE JG et al.: Influence of endothelin on human coronary arteries and localization of its binding sites. Am. J. Cardiol. (1989) 63:1395-1398.
16. PIERRE LN, DAVENPORT AP: Endothelin receptor subtypes and their functional relevance in human small coronary arteries. Br. J. Pharmacol. (1998) 124:499-506.
17. MIYAUCHI T, YANAGISAWA M, TOMIZAW T et al.: Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet (1989) 2:53-54.
18. SALMINEN K, TIKKANEN I, SAIJONMAA O et al.: Modulation of coronary tone in acute myocardial infarction by endothelin. Lancet (1989) 2:747.
19. STEWART DJ, KUBAC G, COSTELLO KB, CERNACEK P: Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J. Am. Coll. Cardiol. (1991) 18:38-43.
20. RAY SG, MCMURRAY JJ, MORTON JJ, DARGIE HJ: Circulating endothelin in acute ischaemic syndromes. Br. Heart J. (1992) 67:383-386.
21. LECHLEITNER P, GENSER N, MAIR J et al.: Endothelin-1 in patients with complicated and uncomplicated myocardial infarction. Clin. Investig. (1992) 70:1070-1072.
22. TOMODA H: Plasma endothelin-1 in acute myocardial infarction with heart failure. Am. Heart. J. (1993) 125:667-672.
23. TSUTAMOTO T, WADA A, HAYASHI M et al.: Relationship between transcardiac gradient of endothelin-1 and left ventricular remodelling in patients with first anterior myocardial infarction. Eur. Heart. J. (2003) 24:346-355.
24. OMLAND T, LIE RT, AAKVAAG A, AARSLAND T, DICKSTEIN K: Plasma endothelin determination as a prognostic indicator of one year mortality after acute myocardial infarction. Circulation (1994) 89:1573-1579.
25. LECHLEITNER P, GENSER N, MAIR J et al.: Plasma immunoreactive endothelin in the acute and subacute phases of myocardial infarction in patients undergoing fibrinolysis. Clin. Chem. (1993) 39:955-959.
26. HASDAI D, HOLMES DR Jr, GARRATT KN, EDWARDS WD, LERMAN A: Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo. Circulation (1997) 95:357-362.
27. SUZUKI H, TAKEYAMA, Y, MATSUBARA H et al.: Plasma endothelin-1 and thrombomodulin levels in coronary sinus during right atrial pacing and percutaneous transluminal coronary angioplasty. Int. J. Cardiol. (2000) 74:15-23.
28. SCHAFER U, KURZ T, JAIN D et al.: Impaired coronary flow and left ventricular dysfunction after mechanical recanalization in acute myocardial infarction: role of neurohumoral activation. Basic Res. Cardiol. (2000) 97:399-408.
29. KYRIAKIDES ZS, MARKIANOS M, ANTONIADIS A et al.: Effect of rotational coronary atherectomy on peripheral endothelin-1, atrial natriuretic peptide, and cyclic adenosine monophosphate plasma levels. Cardiovasc. Drugs Ther. (1998) 11-245-250.
30. WAINSTEIN MV, GONCALVES SC, ZAGO AL et al.: Plasma endothelin-1 levels after coronary stenting in humans. Am. J. Cardiol. (2003) 92:1211-1214.
31. KYRIAKIDES ZS, KREMASTINOS DT, KOLETTIS TM: Acute endothelin-A receptor antagonism prevents normal reduction of myocardial ischemia on repeated balloon inflations during angioplasty. Circulation (2000) 102:1937-1943.
32. GARJANI A, WAINWRIGHT CL, ZEITLIN IJ, WILSON C, SLEE SJ: Effects of endothelin-1 and the ETA-receptor antagonist, BQ 123 on ischemic arrhythmias in anesthetized rats. J. Cardiovasc. Pharmacol. (1995) 25:634-642.
33. SHARIF I, KANE KA, WAINWRIGHT CL: Endothelin and ischaemic arrhythmias - antiarrhythmic or arrhythmogenic. Cardiovasc. Res. (1998) 39:626-632.
34. CROCKETT TR, SCOTT GA, MCGOWAN NW, KANE KA, WAINWRIGHT CL: Anti-arrhythmic and electrophysiological effects of the endothelin receptor antagonists, BQ-123 and PD161721. Eur. J. Pharmacol (2001) 432:71-77.
35. BRUNNER F, DU TOIT EF, OPIE LH: Endothelin release during ischaemia and reperfusion of isolated perfused rat hearts. J. Mol. Cell. Cardiol. (1992) 24:1291-1305.
36. WATANABE T, SUZUKI N, SHIMAMOTO N, FUJINO M, IMADA A. Contribution of endogenous endothelin to the extension of myocardial infarction size in rats. Circ. Res. (1991) 69:370-377.
37. B antagonist. Br. J. Pharmacol. (1994) 113:869-876.
38. LI XS, WANG QD, PERNOW J: Beneficial effects of endothelin receptor antagonist bosentan on myocardial and endothelial injury following ischaemia/reperfusion in the rat Eur. J. Pharmacol. (1995) 283:161-168.
39. GONON AT, WANG QD, PERNOW J: The endothelin A receptor antagonist LU-135252 protects the myocardium from neutrophil injury during ischaemia/reperfusion. Cardiovasc. Res. (1998) 39:674-682.
40. LEE LY, WARNER RB, ADLER AL, OPGENORTH TJ: Endothelin ETA receptor antagonist reduced myocardial infarction induced by coronary artery occlusion and reperfusion in the rat. Pharmacology (1994) 49:319-324.
41. B receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats. Br. J. Pharmacol. (1995) 114:949-954.
42. TAKAHASHI C, KAGAYA Y, NAMIUCHI S et al.: Nonselective endothelin receptor antagonist initiated soon after the onset of myocardial infarction may deteriorate 24-hour survival. J. Cardiovasc. Pharmacol. (2001) 38:29-38.
43. WANG TL, CHANG H, HUNG CR, TSENG YZ: Morphine preconditioning attenuates neutrophil activation in rat models of myocardial infarction. Cardiovasc. Res. (1998) 40:557-563.
44. FRACCAROLLO D, HU K, GALUPPO P, GAUDRON P, ERTL G: Chronic endothelin receptor blockade attenuates progressive ventricular dilation and unproves cardiac function in rats with myocardial infarction. Circulation (1997) 96:3963-3973.
45. FRACCAROLLO D, GALUPPO P, BALTERSACHS J, ERTL G: Collagen accumulation after myocardial infarction: effects of ETA receptor blockade and implications for early remodeling. Cardiovasc. Res. (2002) 54:559-567.
46. CLOZEL M, QIU C, QUI CS, HESS P, CLOZEL JP: Short-term endothelin receptor blockade with tezosentan has both immediate and long-term effects in rats with myocardial infarction. J. Am. Coll. Cardiol. (2002) 39:142-147.
47. CALIGIURI G, LEVY B, PERNOW J, THOREN P, HANSSON GK: Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic nuce. Proc. Natl. Acad. Sci. USA. (1999) 96:6920-6924.
48. WANG P, GALLAGHER KP, DOWNEY JM, COHEN MV: Pretreatment with endothelin-1 mimics ischemic preconditioning against myocardial infarction in isolated rabbit heart. J. Mol. Cell. Cardiol. (1996) 28:579-588.
49. VITOLA JV, FORMAN MR, HOLSINGER JP et al.: Role of endothelin in a rabbit model of acute myocardial infarction: effects of receptor antagonism J. Cardiovasc. Pharmacol. (1996) 28:774-783.
50. A receptor antagonist, FR 139317, on infarct size in a rabbit model of acute myocardial infarction and reperfusion. Br. J. Pharmacol. (1994) 112:75-80.
51. BURKE SE, NELSON RA: Endothelin-receptor antagonist FR 139317 infarct size in a rabbit model when given before, but not after, coronary artery occlusion. J. Cardiovasc. Pharmacol. (1997) 29:87-92.
52. UMEKAWA K, HASEGAWA H, TSUTSUMI T et al.: Pharmacological characterization of a novel sulfonylureid-pyrazole derivative, SM-19712, a potent nonpeptidic inhibitor of endothelin converting enzyme. Jpn. J. Pharmacol. (2000) 84:7-15.
53. ERIKSON JM, VELASCO CE: Endothelin-1 and myocardial preconditioning. Am. Heart J. (1996) 132:84-90.
54. TEERLINK JR, BREU V, SPRECHER U, CLOZEL M, CLOZEL JP: Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. Circ. Res. (1994) 74:105-114.
55. TSUJI S, SAWAMURA A, WATANABE H et al.: Plasma endothelin levels during myocardial ischemia and reperfusion. Life Sci. (1991) 48:1745-1749.
56. KELLY RF, HURSEY TL, SCHAER GL et al.: Cardiac endothelin release and infarct sice, myocardial blood flow, and ventricular function in canine infarction and reperfusion. J. Invest. Med. (1996) 44:575-582.
57. BATTISTINI B, KINGMA JG: Changes in plasma levels of ET-1 and its precursor, big ET-1, in the arterial and venous circulation following double myocardial ischemia-reperfusion injury in dogs. J. Cardiovasc. Pharmacol. (2000) 36:5 (Suppl.) 1:S215-S220.
58. DONCKIER J, HANET C, STOLERU L et al.: Effects of endothelin-1 at pathophysiologic concentrations on coronary perfusion and mechanical function of normal and postischemic myocardium. J. Cardiovasc. Pharmacol. (1994) 23:212-219.
59. GROVER GJ, DZWONCZYK S, PARHAM CS: The endothelin-1 receptor antagonist BQ-123 reduced infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc. Res. (1993) 27:1613-1618.
60. KRAUSE SM, LYNCH JJ Jr, STABILITO, WOLTMANN RF: Intravenous administration of the endothelin-1 BQ-123 does not ameliorate myocardial ischaemic injury following acute coronary artery occlusion in the dog. Cardiovasc. Res. (1994) 28:1672-1678.
61. BASSO C, THIENE G, DELLA BARBERA M et al.: Endothelin A-receptor antagonist administration immediately after experimental myocardial infarction with reperfusion does not affect scar healing in dogs. Cardiovasc. Res. (2002) 55:113-121.
62. SEREBRUANY VL, SCHLOSSBERG ML, EDENBAUM LR, HERZOG WR, GURBEL PA: Serial changes of endothelin-1 levels during myocardial ischaemia-reperfusion. Effects of magnesium, diltiazem and a novel MAC-1 inhibitor. Pharmacol. Res. (1998) 38:165-172.
63. TONNESSEN T, NAESS PA, KIRKEBOEN KA et al.: Release of endothelin from the porcine heart after short term coronary artery occlusion. Cardiovasc. Res. (1993) 27:1482-1485.
64. TONNESSEN T, GIAID A. SALEH D et al.: Increased in vivo expression and production of endothelin-1 by porcine cardiomyocytes subjected to ischemia. Circ. Res. (1995) 76:767-772.
65. WANG QD, LI XS, LUNDBERG JM, PERNOW J: Protective effects of non-peptide endothelin receptor antagonist bosentan on myocardial ischaemic and reperfusion injury in pig. Cardiovasc. Res. (1995) 29:805-812.
66. MERTZ TE, MCCLANAHAN T, FLYNN MA et al.: Endothelin A receptor antagonism by PD 156707 does not reduce infarct size after coronary artery occlusion/reperfusion in pigs. J. Pharmacol. Exp. Ther. (1996) 278:42-49.
67. GONON AT, WANG QD, SHIMIZU M, PERNOW J: The novel non-peptide selective endothelin A receptor antagonist LU 135,252 protects against myocardial ischaemic and reperfusion injury in the pig. Acta Physiol. Scand. (1998) 163:131-137.
68. WENZEL RR, FLEISCH M, SHAW S et al.: Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation (1998) 98:2235-2240.
69. KINLAY S, BEHRENDT S, WAINSTEIN M et al.: Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation (2001) 104:1114-1118.
70. O'CONNOR CM, GATTIS WA, ADAMS JK Jr et al.: Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZonentan study (RITZ-4). J. Am. Coll. Cardiol. (2003) 41:1452-1457.
71. BREHM BR, BUTTCHER E, BEYER ME, HOFFMEISTER HM: Comparison of circulating endothelin-1 and big endothelin-1 levels in unstable versus stable angina pectoris. J. Cardiovasc. Pharmacol. (1998) 31(Suppl. 1):S90-S93.
72. LOCKOWANDT U, BJESSMO S, IVERT T, FRANCO-CERECED A. Plasm levels and vascular effects of endothelin in patients with stable and unstable angina patients undergoing coronary bypass grafting. Eur. J. Cardiothorac. Surg. (2002) 21:218-223.
73. NGUYEN QT, CERNACEK P, SIROIS MG et al.: Long-term effects of non-selective endothelin A and B receptor antagonism in postinfarction rat: importance of timing Circulation (2001) 104:2075-2081.
74. SAKAI S, MIYAUCHI T, YAMAGUCHI I: Long-term endothelin receptor antagonist administration improves alterations in expression of various cardiac genes in failing myocardium of rats with heart failure. Circulation (2000) 101:2879-2853.
75. MULDER P, RICHARD V, DERUMEAUX G et al.: Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation (1997) 96:1976-1982.
76. DOGGRELL SA: The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzymes inhibitors on the cardiovascular system. Expert Opin. Investig. Drugs (2002) 11:1157-1172.
77. A receptor blockade trial. Circulation (2002) 106:2666-2672.
78. WANG TL, CHANG H: Intravenous morphine reduces plasma endothelin 1 concentration through activation of neutral endopeptidase 24.11 in patients with myocardial infarction. Ann. Emerg. Med. (2001) 37:445-449.